New Insights into Disease Progression for the CFTR Modulator-Treated Cystic Fibrosis Patient

Pre-Activity Questions

Currently, how confident are you in your ability to *

Please use the scale: 1=NOT at all confident, 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=EXTREMELY confident

	1	2	3	4	5
Effectively diagnose patients with CF?	Effectively diagnose patients with CF? - 1	Effectively diagnose patients with CF? - 2	Effectively diagnose patients with CF? - 3	Effectively diagnose patients with CF? - 4	Effectively diagnose patients with CF? - 5
Develop treatment plans to optimize patients outcomes?	Develop treatment plans to optimize patients outcomes? - 1	Develop treatment plans to optimize patients outcomes? - 2	Develop treatment plans to optimize patients outcomes? - 3	Develop treatment plans to optimize patients outcomes? - 4	Develop treatment plans to optimize patients outcomes? - 5

Which of the following manifestations of cystic fibrosis would be reversible? *

Fibrosis

Bronchiectasi

Gas trapping

Cirrhosis

A study was conducted to assess the efficacy of ataluren on lung function in patients with CF. Which of the following is true regarding the results of this study? *

There was no significant difference in percent predicted FEV1 when administered with inhaled-antibiotics

There was no significant difference in percent predicted FEV1 when administered without inhaled-antibiotics

There was a significant difference in percent predicted FEV1 when administered without inhaled-antibiotics

Both A and C

PERSIST was an extension trial of the STRIVE and ENVISON trials. Which of the following therapeutics options was observed in these studies? *

Lumacaftor

Ataluren

Ivacaftor

Lumacaftor and ivacaftor combination therapy

True or False: FEV1 change does not predict CFPE reduction. *

True

False

Which of the following is false regarding diagnosing “mild” mutations in CF? *

Diagnosis is usually made later in life

Diagnosis is usually made at infancy

Mild mutations are different to the conventional

None of the above

Which of the following CF disease manifestations is not improved by CFTR modulation? *

Pancreatic function

Diabetes

Airway inflammation

Airway disease

Which of the following statements is true regarding lumcaftor/ivacaftor combination therapy? *

LUM 600 mg qd/IVA 250 mg q12h had the greatest proportion of patients with >5 improvement and >10 improvement in FEV1

LUM 400 mg q12h/IVA 250 mg q12h had the greatest proportion of patients with >5 improvement and >10 improvement in FEV1

Both doses of the combination therapy were equal in the amount of patients with improved FEV1 when compared to placebo

Neither doses of the combination were significant in the amount of patients with improved FEV1 when compared to placebo

Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with cystic fibrosis. *

1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, 6=N/A for me,

	1	2	3	4	5	N/A for me
Recognize improved disease progression in patients who have received CFTR modulation therapy.	Recognize improved disease progression in patients who have received CFTR modulation therapy. - 1	Recognize improved disease progression in patients who have received CFTR modulation therapy. - 2	Recognize improved disease progression in patients who have received CFTR modulation therapy. - 3	Recognize improved disease progression in patients who have received CFTR modulation therapy. - 4	Recognize improved disease progression in patients who have received CFTR modulation therapy. - 5	Recognize improved disease progression in patients who have received CFTR modulation therapy. - N/A for me
Develop optimal treatment strategies to effectively manage patients with CF.	Develop optimal treatment strategies to effectively manage patients with CF. - 1	Develop optimal treatment strategies to effectively manage patients with CF. - 2	Develop optimal treatment strategies to effectively manage patients with CF. - 3	Develop optimal treatment strategies to effectively manage patients with CF. - 4	Develop optimal treatment strategies to effectively manage patients with CF. - 5	Develop optimal treatment strategies to effectively manage patients with CF. - N/A for me
Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans.	Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans. - 1	Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans. - 2	Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans. - 3	Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans. - 4	Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans. - 5	Apply knowledge of current clinical trial data of CFTR modulation therapy into individualized patient treatment plans. - N/A for me
Review updated guidelines and diagnostic strategies to effectively implement them into practice.	Review updated guidelines and diagnostic strategies to effectively implement them into practice. - 1	Review updated guidelines and diagnostic strategies to effectively implement them into practice. - 2	Review updated guidelines and diagnostic strategies to effectively implement them into practice. - 3	Review updated guidelines and diagnostic strategies to effectively implement them into practice. - 4	Review updated guidelines and diagnostic strategies to effectively implement them into practice. - 5	Review updated guidelines and diagnostic strategies to effectively implement them into practice. - N/A for me

Leave this field blank

Elsevier CME

New Insights into Disease Progression for the CFTR Modulator-Treated Cystic Fibrosis Patient

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Course navigation

You are here

New Insights into Disease Progression for the CFTR Modulator-Treated Cystic Fibrosis Patient

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Course navigation